MedTrace Logo

Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes

NCT03254368 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2019-05-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the study drug ZGN-1061 in participants with type 2 diabetes.

Conditions

Interventions

DRUG

ZGN-1061

ZGN-1061 is a methionine aminopeptidase 2 inhibitor

DRUG

Placebo

Placebo has the same excipients and appearance as ZGN-1061

Sponsors & Collaborators

  • Zafgen, Inc.

    lead INDUSTRY

Principal Investigators

  • Dennis Kim, MD · Zafgen, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-12
Primary Completion
2018-11-12
Completion
2019-02-22

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03254368 on ClinicalTrials.gov